Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Viatris Inc (VTRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: VTRS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.39
1 Year Target Price $11.39
| 2 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.42% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.70B USD | Price to earnings Ratio - | 1Y Target Price 11.39 |
Price to earnings Ratio - | 1Y Target Price 11.39 | ||
Volume (30-day avg) 9 | Beta 0.89 | 52 Weeks Range 6.75 - 13.19 | Updated Date 07/12/2025 |
52 Weeks Range 6.75 - 13.19 | Updated Date 07/12/2025 | ||
Dividends yield (FY) 5.38% | Basic EPS (TTM) -3.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.45% | Operating Margin (TTM) 5.67% |
Management Effectiveness
Return on Assets (TTM) 2.23% | Return on Equity (TTM) -21.25% |
Valuation
Trailing PE - | Forward PE 4.17 | Enterprise Value 24160279511 | Price to Sales(TTM) 0.75 |
Enterprise Value 24160279511 | Price to Sales(TTM) 0.75 | ||
Enterprise Value to Revenue 1.69 | Enterprise Value to EBITDA 11.16 | Shares Outstanding 1173680000 | Shares Floating 1165653979 |
Shares Outstanding 1173680000 | Shares Floating 1165653979 | ||
Percent Insiders 0.26 | Percent Institutions 84.99 |
Upturn AI SWOT
Viatris Inc
Company Overview
History and Background
Viatris Inc. was formed in November 2020 through the merger of Mylan N.V. and Upjohn, a division of Pfizer. Mylan's history dates back to the 1960s as a generic drug manufacturer. Upjohn had a long history as part of Pfizer, focusing on established pharmaceutical brands.
Core Business Areas
- Developed Markets: Focuses on developed markets, including North America, Europe, and Australia, selling a wide array of generic and branded pharmaceutical products.
- Emerging Markets: Targets emerging markets like China, India, and Latin America, selling generic drugs and branded medications to address the unique healthcare needs of these regions.
- Biosimilars: Develops and commercializes biosimilar versions of complex biologic drugs, offering more affordable treatment options to patients.
Leadership and Structure
Viatris is led by a management team with experience from both Mylan and Upjohn. The organizational structure consists of global business units and regional teams, reflecting its global presence.
Top Products and Market Share
Key Offerings
- Lipitor (atorvastatin): Lipitor is a branded generic drug for lowering cholesterol. While patent protection has expired, Viatris maintains a significant market share in some regions. Competitors include generic atorvastatin manufacturers and other statin drugs like rosuvastatin (Crestor). Viatris generates a significant portion of its revenue from this product.
- EpiPen (epinephrine auto-injector): EpiPen is an epinephrine auto-injector used to treat severe allergic reactions (anaphylaxis). Viatris owns the brand name product outside of North America. It faces competition from other epinephrine auto-injectors, including generics and alternatives like Auvi-Q. In some markets it is the dominant product and generates significant revenue for Viatris.
- Viagra: Viagra is a branded generic drug used to treat erectile dysfunction. While patent protection has expired, Viatris maintains a significant market share in some regions. Competitors include generic sildenafil manufacturers and other ED drugs like Cialis and Levitra. Viatris generates a significant portion of its revenue from this product.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and ongoing innovation. Generics and biosimilars are increasingly important due to cost pressures on healthcare systems.
Positioning
Viatris is a global pharmaceutical company focused on generic and branded drugs, as well as biosimilars. It aims to provide affordable and accessible medicines worldwide.
Total Addressable Market (TAM)
The global generic drugs market is estimated to be worth hundreds of billions of dollars. Viatris is positioned to capture a significant portion of this market through its extensive product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Global presence and distribution network
- Diverse product portfolio
- Strong focus on generics and biosimilars
- Experienced management team
Weaknesses
- High debt levels
- Integration challenges from the merger
- Dependence on key products
- Complex organizational structure
Opportunities
- Growth in emerging markets
- Increasing demand for biosimilars
- Strategic acquisitions and partnerships
- Expansion of product portfolio
Threats
- Intense competition from generic drug manufacturers
- Pricing pressures and regulatory changes
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- LCI
- PRGO
- PFE
Competitive Landscape
Viatris competes with other generic drug manufacturers, branded pharmaceutical companies, and biosimilar developers. Its strengths include its global scale and diverse product portfolio. Its weaknesses include its debt levels and integration challenges.
Major Acquisitions
Oyster Point Pharma
- Year: 2023
- Acquisition Price (USD millions): 425
- Strategic Rationale: Expands Viatris' ophthalmology portfolio and pipeline, diversifying its product offerings and entering the dry eye disease market.
Growth Trajectory and Initiatives
Historical Growth: Viatris's historical growth trends depends on historical financial data.
Future Projections: Future growth projections depends on analyst estimates.
Recent Initiatives: Viatris is focused on deleveraging its balance sheet, streamlining its operations, and launching new products. They are actively pursuing biosimilar development and expansion into emerging markets.
Summary
Viatris is a global pharmaceutical company with a diverse portfolio of generic and branded drugs. Its strengths include its global scale and focus on affordable medicines. However, the company faces challenges related to debt, integration, and competition. They have undertaken strategic initiatives to focus on key products and markets to improve profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions are dynamic and can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viatris Inc
Exchange NASDAQ | Headquaters Canonsburg, PA, United States | ||
IPO Launch date 2020-11-16 | CEO & Director Mr. Scott Andrew Smith Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 32000 | Website https://www.viatris.com |
Full time employees 32000 | Website https://www.viatris.com | ||
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.